MTD Group以1.1bn欧元购买了Ypcomed的笔线和血糖监测系统。 MTD Group acquires Ypsomed's Pen Needles and Blood Glucose Monitoring Systems for €1.1bn.
MTD集团是一家医疗技术公司,以1.1bn欧元购买Ypcomed的笔线和血糖监测系统,加强了它作为笔针市场上第二大玩家的地位。 MTD Group, a medtech company, acquires Ypsomed's Pen Needles and Blood Glucose Monitoring Systems for €1.1bn, strengthening its position as the 2nd largest player in the pen needles market. 该协议包括先进的技术和商标,以及欧洲建立尖端生产设施的MTD计划。 The deal includes advanced technologies and trademarks, and MTD plans to establish cutting-edge production facilities in Europe. 收购还允许进入中国和印度等高增长市场,扩大MTD在既有市场中的存在。 The acquisition also grants access to high-growth markets like China and India, and expands MTD's presence in established markets.